TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01620450
Drug: biphasic human insulin 30
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits
Study: NCT00527969
Drug: HT1001 extract of Panax quinquefolius L
Normalized name: Panax quinquefolius whole extract
DrugBank: Panax quinquefolius whole (DB14296)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02899182
Drug: Nitrous Oxide NO
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
Study: NCT03904251
Drug: Gemtuzumab Ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT03904251
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02569801
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant at a dose of 500 mg as two intramuscular injections will be administered on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle.
Study: NCT02569801
Drug: GDC-0810
Normalized name: GDC-0810
DrugBank: GDC-0810 (DB12253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0810 will be administered as tablets at a dose of 600 mg orally once daily.
Study: NCT00428246
Drug: paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mcg or 2 mcg for 4 weeks.
Study: NCT00452296
Drug: tight insulin treatment in patients hospitalized with COPD exacerbation
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment with basal plus bolus insulin
Study: NCT00762255
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
Study: NCT00762255
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
Study: NCT03890289
Drug: Idelalisib
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
Study: NCT00762255
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
Study: NCT00606112
Drug: Trodusquemine (MSI-1436)
Normalized name: morphine sulfate Oral Solution [MSIR]
DrugBank: Trodusquemine (DB06333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose will be administered on Day 0. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2, 10mg/m2 in cohort 3 and 15mg/m2 in cohort 4/
Study: NCT03995485
Drug: KW-136 capsule
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-136 60 mg was provided in a single capsule of 60 mg.
Study: NCT03995485
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir was provided in a single tablet of 400 mg.
Study: NCT03890289
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
Study: NCT04269369
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The aim of this study is to investigate if the systematic implementation of pre-emptive geno- and phenotyping, and therefore a dose reduction based on the French guidelines and the literature during the first month of treatment, reduces grade 3 or greater toxicity in patients treated with 5-FU or capecitabine. Therefore a dosing table was obtained by combining the results of the study by Henricks et al., Launay et al. and Yang et al. and the recommendations from the French HAS guideline. The treatment schedule then will be discussed by the team of doctors and paramedics at the weekly MOC (multidisciplinary cancer consultation). Complementary, the pharmacist provides dose advice with regard to the start of 5-FU or capecitabine treatment.~In a subgroup, the group of patients with genotype wild type and phenotype intermediate metabolizer, a comparison will be made between group A with dosage according to French guidelines and group B with dosage according to literature.
Study: NCT00916669
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide given as an infusion on day 1, day 2 and day 3 of a three-week cycle for a total of 6 cycles
Study: NCT00916669
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given as an infusion on day 1 of a three-week cycle for a total of 6 cycles
Study: NCT00916669
Drug: enoxaparin sodium
Normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given as a subcutaneous injection in the abdomen daily during chemotherapy treatment and then continuing daily for 1 year. Dose will vary.
Study: NCT04477707
Drug: Finerenone (BAY94-8862)
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO or FIGARO clinical trial.
Study: NCT02271334
Drug: A006 DPI
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose 110 mcg, 1 inhalation
Study: NCT02271334
Drug: A006 DPI
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose 220 mcg, 1 inhalation
Study: NCT00766012
Drug: AZD2066
Normalized name: AZD2066
DrugBank: AZD2066 (DB17078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16. Specific dose depends on dose panel.
Study: NCT00299325
Drug: Rimonabant
Normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tablet, oral administration
Study: NCT00253435
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The carboplatin will be administered as a continuous IV infusion Day - 7 through Day - 4, with dosing based upon pretreatment GFR levels. The carboplatin should be diluted to a concentration of 0.3 mg/ml in D5W 0.45NS and infused concomitantly with etoposide through the same central venous catheter using a Y connector; a controlled rate infusion pump is used for each arm of the Y.
Study: NCT00253435
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The etoposide shall be administered day -7 through day -4 via continuous intravenous infusion over 96 hours. For patients with a corrected GFR \>= 100 ml/min/1.72 m\^2, a dose of 300 mg/m\^2/day (10 mg/kg/day if child is \< 12 kg) shall be given. For patients with a corrected GFR 60-99 ml/min/1.72 m\^2, the etoposide will be administered at a dose of 160 mg/m\^2/day (5.3 mg/kg/day). The etoposide will be diluted in D5W 0.45%NS at a concentration of \< 0.4 mg/ml. Etoposide should not be mixed with carboplatin, but administered using a Y-connector.
Study: NCT00253435
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For patients in either the normal GFR strata (\>=100 ml/min/1.73 m\^2), or reduced GFR strata (60-99 ml/min/1.73m\^2), melphalan shall be administered at a dose of 60 mg/m\^2/day (2 mg/kg/day if child is \< 12 kg) on day -7, -6, and -5 of study. The melphalan should be infused at a rate of less than 10 mg/minute, and should complete within 1 hour of reconstitution each day. The melphalan should be diluted in 0.9% NaCl at a concentration \< 2 mg/ml. The total dosage of melphalan to be administered will be 180 mg/m\^2.
Study: NCT01946620
Drug: Formoterol
Normalized name: Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03779230
Drug: L19TNF
Normalized name: Daromun component l19tnf
DrugBank: Onfekafusp alfa (DB16269)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
Study: NCT05468294
Drug: Nivolumab, fixed dose
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 3 mg/kg of Nivolumab as a 60 minutes i.v. infusion on day 1 and day 15 of each 28-days cycle.
Study: NCT00917748
Drug: DOCETAXEL(XRP6976) + MODAFINIL
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: arm 1: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily arm 2: best supportive care (docetaxel chemotherapy) plus placebo of modafinil 200mg mane daily
Study: NCT00917748
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily
Study: NCT00917748
Drug: Placebo of Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Best supportive care (docetaxel chemotherapy) + placebo capsules one daily-mane (before noon)
Study: NCT02179892
Drug: Bupivacaine Extended-Release Liposome Injection (Exparel)
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 266mg/30mL of Exparel will be injected via unilateral TAP block
Study: NCT02179892
Drug: Bupivacaine and Dexamethasone Injection
Normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone will be injected via unilateral TAP block.
Study: NCT03489668
Drug: MetFORMIN 500 Mg Oral Tablet
Normalized name: metFORMIN 500 mg oral tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin administration 1500mg per day
Study: NCT01915602
Drug: Refametinib (BAY86-9766)
Normalized name: Refametinib
DrugBank: Refametinib (DB06309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive refametinib 50 mg (2x20 mg + 1x10mg capsules or 50 mg tablets) bid
Study: NCT01915602
Drug: Sorafenib (BAY43-9006)
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive sorafenib 400 mg (2 x 200 mg tablets) bid.
Study: NCT00014430
Drug: vinorelbine ditartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (trade name Navelbine) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer.
Study: NCT00305019
Drug: clevudine
Normalized name: clevudine
DrugBank: Clevudine (DB06683)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04468568
Drug: Atosiban
Normalized name: atosiban
DrugBank: Atosiban (DB09059)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Atosiban intravenous. Dose: attack of 6.75 mg, and maintenance of 300 mcg / min for 3 hours, and 100 mcg / min for 21 hours.
Study: NCT04468568
Drug: Terbutaline
Normalized name: Terbutaline
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline intravenous. Dose: 2.5 mg in 500 mL saline, infusion rate of 30 mL / hr (150 mcg / h) during the surgery and for 24 hours.
Study: NCT03332355
Drug: PAC-1 Compound
Normalized name: PAC-1
DrugBank: PAC-1 (DB13048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC-1 in combination with temozolomide (Component 2): after the MTD is established for single agent PAC-1 in Component 1, a modified-Fibonacci dose-escalation 3+3 design starts in Component 2, at a PAC-1 dose one level lower than the MTD of PAC-1 established in the single agent PAC-1 component (i.e., Component 1). PAC-1 will be taken in the morning on days 1-21 in each 28 day cycle. Temozolomide 150 mg/m2 dose is given for the 5 days starting at day 8 of cycle 1 in cohorts of 3-6 patients. The combination cohort that reaches MTD will expanded to at least 9 patients, similar to the PAC-1 alone cohort at MTD.
Study: NCT03193684
Drug: Empagliflozin 25 MG
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subjects will receive daily dose of 25mg of empagliflozin for 3 months
Study: NCT03193684
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo
Study: NCT02052024
Drug: Botox
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Treatment group will receive 100 units of BOTOX and subjects will receive 1-3 injections per muscle at each visit.
Study: NCT02052024
Drug: MYOBLOC
Normalized name: Myobloc
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group will receive 5,000 units of MYOBLOC and subjects will receive 1-3 injections per muscle at each visit.
Study: NCT02159131
Drug: Ethinyl Estadiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: EE is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
Study: NCT02159131
Drug: Levonorgestrel
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LNG is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
Study: NCT00274261
Drug: C31G
Normalized name: C31G
DrugBank: C31G (DB05398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.
Study: NCT00620945
Drug: Phenoxybenzamine
Normalized name: Phenoxybenzamine
DrugBank: Phenoxybenzamine (DB00925)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of Phenoxybenzamine:~Loading dose given at the time of going on CPB:~* For patients with obstructing lesions on systemic side:~  * 0.25 mg/kg dose in the bypass circuit~ * None intravenous~* For patients without obstructing left sided lesions:~  * 0.5 mg/kg in the bypass circuit~ * 0.5 mg/kg I.V. at cannulation~Maintenance dose given in the post-operative period:~* 0.3 mg/kg I.V. every 8 hours till oral intake is started or for first 48 hours~* 0.3 mg/kg P.O. every 8 hours for next 24 hours~* 0.15 mg/kg P.O. every 8 hours for next 24 hours and then stop~* Hold PBZ if the patient is on norepinephrine infusion or the mean arterial pressure is lower than that allowed for the age group
Study: NCT02092298
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C 30 mg delivered laparoscopically for 60 minutes.
Study: NCT02092298
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.
Study: NCT02092298
Drug: Sodium Thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.
Study: NCT01711762
Drug: GDC-0973
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of \[14C\]-GDC-0973
Study: NCT02570789
Drug: patients with sunitinib or pazopanib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The treatment with sunitinib or pazopanib should comply with the recommendations written in the Belgian product information and the reimbursement criteria
Study: NCT03974867
Drug: Prednisone 5Mg Tab
Normalized name: PREDNISONE 5MG TAB
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucocorticoids:~d1-d7: Oral Pred. 1mg/kg/d a (maximum daily dosage is no more than 60mg); d8-d9: Oral Pred. 10mg less than d7; d10-d11: Oral Pred. 10mg less than d9; d12: Oral Pred. 10mg less than d11; d13: Oral Pred. 10mg less than d12; d14: Oral Pred. 10mg less than d13;
Study: NCT03247790
Drug: Lasmiditan
Normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT03974867
Drug: Methylprednisolone 40 mg
Normalized name: methylprednisolone 40 MG
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucocorticoids:~7 intratympanic injections of 40mg/ml Met. in 14 days, one injection every other day;
Study: NCT01332344
Drug: Fluticasone propionate/salmeterol combination
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Asthma subjects newly prescribed fluticasone propionate/salmeterol combination
Study: NCT00660517
Drug: azelastine Hcl
Normalized name: azelastine HCl
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: azelastine Hcl nasal spray one spray per nostril two times a day
Study: NCT00660517
Drug: fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: fluticasone propionate 200 mcg nasal spray one spray per nostril two times a day
Study: NCT00063726
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04299880
Drug: Napabucasin
Normalized name: Napabucasin
DrugBank: Napabucasin (DB12155)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04299880
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous
Study: NCT04299880
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous
Study: NCT00519116
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00519116
Drug: Perioperative Corticosteroids
Normalized name: abiraterone and corticosteroids
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The corticosteroids use was left up to the investigators decision.
Study: NCT00671112
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be assigned to one of the following dose levels of Bortezomib: 0.7mg/m2, 1.0 mg/m2, or 1.3mg/m2 on days 1,4,8,11 of a 21 day cycle.~The appropriate amount of bortezomib will be drawn from the injection vial and administered as an intravenous (IV) push or sub-cutaneously over 3 to 5 seconds followed by a standard saline flush or through a running IV line.
Study: NCT00671112
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 5 mg PO every other day, 5 mg by mouth (PO) daily, or 10 mg PO daily
Study: NCT04299880
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous
Study: NCT04299880
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous
Study: NCT04299880
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous
Study: NCT04299880
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous
Study: NCT00526630
Drug: Methylphenidate (MPD)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given 1 mg/kg of MPD divided in three doses (at 8 am, 12 noon, and 4 pm). A four-week titration period will be used, using 0.25-mg/kg increments per week until achieving the weight-adjusted target dosage, which may range from five to eight 10-mg tablets per day. The maximum daily dose will be 80 mg/day.
Study: NCT02001311
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04469595
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 mg/0.05 mL Aflibercept Anti-VEGF intravitreal injection
Study: NCT02208843
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib tablet once daily until progression
Study: NCT01422213
Drug: Vortioxetine (Lu AA21004)
Normalized name: Vortioxétine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: encapsulated tablets; daily; orally
Study: NCT00180882
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02547012
Drug: esomeprazole+amox+levo+tetra
Normalized name: esomeprazole, amoxicillin and clarithromycin
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
Study: NCT02547012
Drug: esomeprazole+amox+levo
Normalized name: esomeprazole, amoxicillin and clarithromycin
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.,
Study: NCT01197534
Drug: fostamatinib
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fostamatinib 100 mg twice daily
Study: NCT01197534
Drug: fostamatinib
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fostamatinib 100 mg twice daily/ 150 mg once daily
Study: NCT01197534
Drug: placebo, fostamatinib
DrugBank: Tamatinib (DB07159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.
Study: NCT01862978
Drug: Nadroparin
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no